At 60 days, survival among patients hospitalized with severe alcohol-related hepatitis was no higher with amoxicillin-clavulanate combined with prednisolone than with prednisolone alone, researchers report.
In the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials, the sphingosine 1-phosphate (S1P) receptor modulator etrasimod was useful and safe for induction
In patients with chronic pouchitis following restorative proctocolectomy with ileal pouch–anal anastomosis (IPAA) in patients with ulcerative colitis, the gut-selective monoclonal antibody vedolizumab induced remission
The annual rate of hospitalizations and proportion per year of acute liver failure (ALF) cases involving acetaminophen (paracetamol) and opioids fell in the years after
In a Mendelian randomization (MR) study, associations were identified between genetic variants associated with type 2 diabetes and increased risk of several gastrointestinal diseases (GD),
A first-in-class small interfering RNA (siRNA), lumasiran was safe and effective in a phase 3 trial for reducing urinary and plasma oxalate (POx) in patients
Prenatal or infant exposure to acid-suppressive medications (ASMs) was not associated with allergic diseases in offspring, researchers report. “However, infant exposure to ASMs was associated
Promising medications, biologics, and interventions that address the pathophysiology of alcohol-associated hepatitis are in clinical trials, according to the authors of a review article. Liver
Weekly subcutaneous doses of the fully human monoclonal antibody dupilumab improved histologic outcomes and alleviated symptoms in patients with eosinophilic esophagitis, researchers report. Dupilumab is
Insured patients with chronic hepatitis C (CHC) had better hepatic and nonhepatic outcomes and improved long-term survival after treatment with direct-acting antiviral agents (DAAs), a